U.S., May 12 -- ClinicalTrials.gov registry received information related to the study (NCT07577505) titled 'Histidine Supplementation for Antitumor Immunity in Colorectal Cancer' on April 24.
Brief Summary: The goal of this clinical study is to learn whether oral histidine supplementation may be safely used to support antitumor immune function during standard colorectal cancer treatment.
Participants with colorectal cancer in the supplementation group will:
Take 2g oral histidine once daily during standard colorectal cancer treatment; Provide blood samples before and after supplementation; Attend regular follow-up visits for laboratory tests, safety assessment, and treatment evaluation.
Study Start Date: May, 2026
Study Type: INTERVENT...